Tenax Therapeutics, Inc.
TENX
$5.80
$0.030.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.70M | 1.51M | 1.34M | 1.23M | 1.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.29M | 4.62M | 3.67M | 3.91M | 3.34M |
| Operating Income | -7.29M | -4.62M | -3.67M | -3.91M | -3.34M |
| Income Before Tax | -6.27M | -3.96M | -3.58M | -3.80M | -3.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.27M | -3.96M | -3.58M | -3.80M | -3.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.27M | -3.96M | -3.58M | -3.80M | -3.23M |
| EBIT | -7.29M | -4.62M | -3.67M | -3.91M | -3.34M |
| EBITDA | -7.29M | -4.62M | -3.67M | -3.91M | -3.34M |
| EPS Basic | -0.18 | -0.19 | -1.83 | -3.12 | -10.80 |
| Normalized Basic EPS | -0.11 | -0.12 | -1.14 | -1.95 | -6.75 |
| EPS Diluted | -0.18 | -0.19 | -1.83 | -3.12 | -10.80 |
| Normalized Diluted EPS | -0.11 | -0.12 | -1.14 | -1.95 | -6.75 |
| Average Basic Shares Outstanding | 35.29M | 21.16M | 1.96M | 1.22M | 298.80K |
| Average Diluted Shares Outstanding | 35.29M | 21.16M | 1.96M | 1.22M | 298.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |